Nijmegen 2021: Bridging Radiotherapy & Immunotherapy - PDF Version
30 September  – 1 October 2021, Nijmegen, The Netherlands


This international two-day meeting in Nijmegen, The Netherlands, on 30 September to 1 October  2021, will focus on the combination of radiotherapy and immunotherapy and offers an attractive scientific program with excellent (inter)national speakers.
The majority of cancer patients will undergo radiotherapy during the course of their disease. Combining this local treatment with immunotherapy offers an exciting opportunity to enhance potential systemic effects, which could lead to more successful and less toxic outcomes for many cancer patients.

Additionally, the recent clinical introduction of magnetic resonance (MR)-guided radiotherapy will allow for delivering doses per fractions of radiation that are more likely to induce an anti-tumor response than is currently feasible. In depth immuno-radiomics analyses, and further integration of (functional) imaging and biomarkers in adaptive treatment protocols will help to establish what combinations and conditions will be most effective.

 A number of (inter)nationally renowned speakers will present their latest findings on the following topics:

  • DNA recognition and repair
  • Radio-immunotherapy
  • Metabolism & Imaging
  • Omics & Radiomics

We prefer an onsite live meeting, but in case of continuing pandemic issues all possibilities to partially have the symposium as an online event are foreseen.

On the congress website you will find more information on the scientific programme and how to register. We look forward to welcoming you at the congress in Nijmegen or online in the virtual meeting!

The organising committee:

Prof dr. Marcel Verheij, MD, PhD
Dr. Marleen Ansems, PhD
Dr. Paul N. Span, PhD